Emergent BioSolutions secures $17M contract modification from BARDA

Emergent BioSolutions (EBS) announced it has received a $17M contract modification from the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ASPR, within the U.S. Department of Health and Human Services, HHS, to supply TEMBEXA oral suspension. This follows the U.S. Food and Drug Administration’s recent approval of the manufacturing scale-up of TEMBEXA oral suspension. “Our newly secured contract modification and ongoing collaboration with BARDA and its procurement of TEMBEX oral suspension formulation reinforces the critical need for a continuous supply of countermeasures to help address smallpox disease among vulnerable patient populations during a potential outbreak,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We are proud of our efforts to increase manufacturing scale to respond to customers’ immediate needs by strengthening our U.S. manufacturing and supply chain process and serving as a trusted partner supporting the U.S. government to address this serious national health security threat.”